Rigid crosslinking of the CD3 complex leads to superior T cell stimulation.
CD3 Complex
/ immunology
Humans
T-Lymphocytes
/ immunology
Immunoglobulin Fab Fragments
/ immunology
Lymphocyte Activation
/ immunology
Animals
Receptors, Antigen, T-Cell
/ immunology
Protein Binding
Molecular Dynamics Simulation
Receptor-CD3 Complex, Antigen, T-Cell
/ immunology
Mice
Antibodies, Monoclonal
/ immunology
Signal Transduction
Binding Sites
CD3/antibody crosslinking
EAE (experimental autoimmune encephalomyelitis)
T cell division and apoptosis
T cell receptor engagement and triggering
anti-CD3 Fab-based therapies
antibody fragment structure
molecular dynamic simulation
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
17
05
2024
accepted:
07
08
2024
medline:
17
9
2024
pubmed:
17
9
2024
entrez:
16
9
2024
Statut:
epublish
Résumé
Functionally bivalent non-covalent Fab dimers (Bi-Fabs) specific for the TCR/CD3 complex promote CD3 signaling on T cells. While comparing functional responses to stimulation with Bi-Fab, F(ab')2 or mAb specific for the same CD3 epitope, we observed fratricide requiring anti-CD3 bridging of adjacent T cells. Surprisingly, anti-CD3 Bi-Fab ranked first in fratricide potency, followed by anti-CD3 F(ab')2 and anti-CD3 mAb. Low resolution structural studies revealed anti-CD3 Bi-Fabs and F(ab')2 adopt similar global shapes with CD3-binding sites oriented outward. However, under molecular dynamic simulations, anti-CD3 Bi-Fabs crosslinked CD3 more rigidly than F(ab')2. Furthermore, molecular modelling of Bi-Fab and F(ab')2 binding to CD3 predicted crosslinking of T cell antigen receptors located in opposing plasma membrane domains, a feature fitting with T cell fratricide observed. Thus, increasing rigidity of Fab-CD3 crosslinking between opposing effector-target pairs may result in stronger T cell effector function. These findings could guide improving clinical performance of bi-specific anti-CD3 drugs.
Identifiants
pubmed: 39281668
doi: 10.3389/fimmu.2024.1434463
pmc: PMC11392757
doi:
Substances chimiques
CD3 Complex
0
Immunoglobulin Fab Fragments
0
Receptors, Antigen, T-Cell
0
Receptor-CD3 Complex, Antigen, T-Cell
0
Antibodies, Monoclonal
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1434463Informations de copyright
Copyright © 2024 Nelson, Wang, Laffey, Becher, Parks, Hoffmann, Galeano, Mangalam, Teixeiro, White, Schrum, Cannon and Gil.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.